Gati Asma, Lajmi Nesrine, Derouiche Amine, Marrakchi Raja, Chebil Mohamed, Benammar-Elgaaied Amel
Universite Tunis, El Manar, Tunisie.
Tunis Med. 2011 Oct;89(10):779-83.
Prostate cancer is the second leading cause of men cancer-related death. Cancer immunotherapy has been investigated as a treatment which might be instituted at the point of detection of androgen-independent metastatic disease.
to investigate the expression and humoral response against NYESO-1 in patients with prostate cancer (PC) and to analyze the relationship between expression of NY-ESO-1 and clinicopathological features.
NY-ESO-1 mRNA in surgically resected PC and benign prostatic hyperplasia (BPH) were examined by reverse transcriptionpolymerase chain reaction. The antibody response to NY-ESO-1 was examined by enzyme-linked Elisa assay using recombinant NYESO-1 protein.
NY-ESO-1 mRNA was detected in 9 of 23 (39%) PC patients. Antibodies against NY-ESO-1 protein were detected in 12 of 23 (52%) sera of PC patients and in 5 of 9 (55%) of NY-ESO-1 expressing tumors. However, no mRNA copy or NY-ESO-1 antibodies were detected in all BPH patients tested.
The present study has demonstrated the expression of NY-ESO-1mRNA in prostate Cancer patients and NY-ESO-1 antibody production. Our data suggest that NY-ESO-1 could be used as a tumor marker and constitute a good candidate for vaccine-based immunotherapy for hormonal resistant prostate cancer patients.
前列腺癌是男性癌症相关死亡的第二大主要原因。癌症免疫疗法已被研究作为一种可能在检测到雄激素非依赖性转移性疾病时实施的治疗方法。
研究前列腺癌（PC）患者中NYESO-1的表达及体液反应，并分析NY-ESO-1表达与临床病理特征之间的关系。
采用逆转录聚合酶链反应检测手术切除的PC和良性前列腺增生（BPH）组织中的NY-ESO-1 mRNA。使用重组NYESO-1蛋白通过酶联免疫吸附测定法检测对NY-ESO-1的抗体反应。
23例PC患者中有9例（39%）检测到NY-ESO-1 mRNA。23例PC患者血清中有12例（52%）检测到抗NY-ESO-1蛋白抗体，在9例表达NY-ESO-1的肿瘤中有5例（55%）检测到。然而，在所有检测的BPH患者中均未检测到mRNA拷贝或NY-ESO-1抗体。
本研究证实了前列腺癌患者中NY-ESO-1mRNA的表达及NY-ESO-1抗体的产生。我们的数据表明，NY-ESO-1可作为一种肿瘤标志物，并成为激素抵抗性前列腺癌患者基于疫苗的免疫治疗的良好候选物。
